Altamira Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference
HAMILTON, BERMUDA / ACCESSWIRE / January 5, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its Chairman and CEO, Thomas Meyer, will present at the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022.
The presentation will be available on-demand through the H.C. Wainwright conference portal. Beginning at 7:00 AM Eastern Time (13:00 PM Central European Time) on Monday, January 10, 2022, the presentation will also be available on the Company’s website at www.altamiratherapeutics.com under “Events and Presentations” in the “Investors & Media” section.
About Altamira Therapeutics
Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or for the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol “CYTO”.
Investor contact:
Stephen Kilmer
646.274.3580
sjk@altamiratherapeutics.com
SOURCE: Altamira Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/681058/Altamira-Therapeutics-to-Participate-in-the-HC-Wainwright-BioConnect-Virtual-Conference
